FLT3 and acute myeloid leukemia: what is the wild type receptor up to?
Levis
Mark
M
Department of Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, USA. levisma@jhmi.edu
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D004790:Enzyme Induction; D006801:Humans; D007951:Leukemia, Myeloid / Q000201:enzymology* / Q000235:genetics; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3